Collegium Pharmaceutical released its full‑year 2026 guidance, projecting product revenues of $805 million to $825 million and adjusted EBITDA of $455 million to $475 million.
The guidance includes a forecast for Jornay PM net revenue of $190 million to $200 million, with the remainder of the revenue range coming from the company’s legacy pain portfolio. The mix reflects confidence in the company’s expanding ADHD franchise and the durability of its pain‑management products’ regulatory and manufacturing advantages.
Management noted that the guidance builds on the record performance reported for 2025 and expects to maintain or improve its adjusted EBITDA margin. The company will continue to focus its capital deployment on debt repayment, share repurchases, and selective acquisitions to reinforce shareholder value.
Investors will be watching how the 2026 results compare to the guidance, particularly the balance between high‑margin pain products and the high‑growth ADHD line. The guidance signals a continued growth trajectory and a disciplined operating model that aims to generate cash flow while pursuing new opportunities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.